Association Study between Novel CYP26 Polymorphisms and the Risk of Betel Quid-Related Malignant Oral Disorders
Table 2
Distribution of CYP26 families genotype and allele frequency among malignant oral disorders patients and control groups.
Oral and pharyngeal cancer ()
OPMDs ()
Controls ()
Oral and pharyngeal cancer versus controls
OPMDs versus controls
BQ chewers
(%)
(%)
(%)
aOR (95% CI)
aOR (95% CI)
CYP26A1
rs4411227
Genotype
G/G
130 (61.61)
40 (71.43)
170 (77.98)
1.00
1.00
C/G
74 (35.07)
14 (25.00)
43 (19.72)
2.38 (1.48–3.84)b*
0.0004
1.39 (0.67–2.90)
0.3792
C/C
7 (3.32)
2 (3.57)
5 (2.29)
1.65 (0.46–5.95)
0.4417
0.80 (0.09–7.46)
0.8430
Combined genotype
G/G
130 (61.61)
40 (71.43)
170 (77.98)
1.00
1.00
C/C + C/G
81 (38.39)
16 (28.57)
48 (22.02)
2.30 (1.45–3.64)*
0.0004
1.33 (0.65–2.70)
0.4389
Allele
G
334 (79.15)
94 (83.93)
383 (87.84)
1.00
1.00
C
88 (20.85)
18 (16.07)
53 (12.16)
1.93 (1.30–2.88)*
0.0012
1.22 (0.65–2.29)
0.5447
CYP26B1
rs887844
Genotype
G/G
115 (54.50)
25 (44.64)
133 (61.01)
1.00
1.00
A/G
96 (45.50)
31 (55.36)
85 (38.99)
1.38 (0.91–2.09)
0.1273
1.87 (1.01–3.49)*
0.0482
Allele
G
326 (77.25)
81 (72.32)
351 (80.50)
1.00
1.00
A
96 (22.75)
31 (27.68)
85 (19.50)
1.26 (0.89–1.80)
0.1941
1.55 (0.93–2.57)
0.0898
rs3768647
C/G
103 (48.82)
34 (60.71)
218 (100.00)
1.00
1.00
G/G
108 (51.18)
22 (39.29)
0 (0.00)
—a
—a
Allele
C
103 (24.41)
34 (30.36)
218 (50.00)
1.00
1.00
G
319 (75.59)
78 (69.64)
218 (50.00)
3.12 (2.28–4.27)*
<0.0001
2.23 (1.40–3.54)*
0.0007
rs9309462
T/T
198 (93.84)
52 (92.86)
216 (99.08)
1.00
1.00
C/T
13 (6.16)
4 (7.14)
2 (0.92)
9.24 (1.90–45.00)*
0.0059
8.17 (1.25–53.52)*
0.0285
Allele
T
409 (96.92)
108 (96.43)
434 (99.54)
1.00
1.00
C
13 (3.08)
4 (3.57)
2 (0.46)
8.86 (1.84–42.59)*
0.0065
7.87 (1.22–50.54)*
0.0298
aOR was adjusted by continuous age, ethnicity, education level, alcohol drinking, and cigarette smoking habits.
aNonestimated: because the number of samples is equal to zero. .
